View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 5, 2021updated 06 Apr 2021 10:05am

Johnson & Johnson expands Covid-19 vaccine trial to adolescents

Johnson & Johnson (J&J) has expanded Phase IIa clinical trial of Covid-19 vaccine candidate to include adolescent subjects aged 12 to 17 years. 

Johnson & Johnson (J&J) has expanded Phase IIa clinical trial of Covid-19 vaccine candidate to include adolescent subjects aged 12 to 17 years.

Developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, the single-shot vaccine is authorised for emergency use for active immunisation to prevent Covid-19 in adults.

The randomised, double-blind, placebo-controlled study had begun in September last year. It was primarily designed to assess the safety, reactogenicity and immunogenicity of single-dose and two-dose regimens of the vaccine candidate in healthy adults aged 18 to 55 years and elderly individuals aged 65 years and above.

It will also analyse possible vaccination schedules at one, two and three-month intervals in two-dose vaccine regimens.

Johnson & Johnson executive committee vice-chairman and chief scientific officer Paul Stoffels said: “The Covid-19 pandemic has had a profound impact on adolescents, not just with the complications of the disease, but with their education, mental health, and wellbeing.

“It is vital that we develop vaccines for everyone, everywhere, to help combat the spread of the virus with the goal to return to everyday life.”

In the initial stage, the vaccine candidate will be evaluated in a smaller number of adolescents. On reviewing the initial data from the Phase IIa trial, the study will be extended to a bigger group of younger adolescents in a stepwise manner.

Currently, the trial is enrolling subjects in Spain and the UK, with enrolment set to begin in the US, the Netherlands and Canada, Brazil and Argentina soon.

Johnson & Johnson Janssen Research & Development global head Mathai Mammen said: “In addition to expanding this ongoing study to include adolescents, we are in discussions with health authorities and are hard at work to initiate studies in pregnant women and children in the near future.”

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU